Tags

Type your tag names separated by a space and hit enter

Effects of topically applied clobetasol-17-propionate on histamine release in human skin.
Acta Derm Venereol. 1984; 64(3):239-42.AD

Abstract

The effects of topical glucocorticoid treatment on histamine responses and histamine release induced by the histamine liberating agent compound 48/80 were studied in 17 healthy volunteers. The potent glucocorticoid ointment clobetasol-17-propionate was applied on one upper arm of each individual 14, 4 and 2 hours before testing. The other arm was treated in the same way with the corresponding vehicle. Solutions of histamine and compound 48/80 were injected intradermally in both arms. The size of the flare reaction and the duration of the itch response were recorded. It was found that the flare reactions evoked by histamine were slightly (p less than 0.05) reduced on the steroid-pretreated arm whereas the responses to compound 48/80 were much more suppressed (p less than 0.01). Glucocorticoid treatment did not influence the itch responses to histamine while the itch duration following injection of compound 48/80 was significantly reduced in steroid-treated skin compared to control skin. Our results indicate that topical glucocorticoid treatment can suppress histamine release from dermal mast cells in man.

Authors

No affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Controlled Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

6204486

Citation

Ståhle, M, and O Hägermark. "Effects of Topically Applied Clobetasol-17-propionate On Histamine Release in Human Skin." Acta Dermato-venereologica, vol. 64, no. 3, 1984, pp. 239-42.
Ståhle M, Hägermark O. Effects of topically applied clobetasol-17-propionate on histamine release in human skin. Acta Derm Venereol. 1984;64(3):239-42.
Ståhle, M., & Hägermark, O. (1984). Effects of topically applied clobetasol-17-propionate on histamine release in human skin. Acta Dermato-venereologica, 64(3), 239-42.
Ståhle M, Hägermark O. Effects of Topically Applied Clobetasol-17-propionate On Histamine Release in Human Skin. Acta Derm Venereol. 1984;64(3):239-42. PubMed PMID: 6204486.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of topically applied clobetasol-17-propionate on histamine release in human skin. AU - Ståhle,M, AU - Hägermark,O, PY - 1984/1/1/pubmed PY - 1984/1/1/medline PY - 1984/1/1/entrez SP - 239 EP - 42 JF - Acta dermato-venereologica JO - Acta Derm Venereol VL - 64 IS - 3 N2 - The effects of topical glucocorticoid treatment on histamine responses and histamine release induced by the histamine liberating agent compound 48/80 were studied in 17 healthy volunteers. The potent glucocorticoid ointment clobetasol-17-propionate was applied on one upper arm of each individual 14, 4 and 2 hours before testing. The other arm was treated in the same way with the corresponding vehicle. Solutions of histamine and compound 48/80 were injected intradermally in both arms. The size of the flare reaction and the duration of the itch response were recorded. It was found that the flare reactions evoked by histamine were slightly (p less than 0.05) reduced on the steroid-pretreated arm whereas the responses to compound 48/80 were much more suppressed (p less than 0.01). Glucocorticoid treatment did not influence the itch responses to histamine while the itch duration following injection of compound 48/80 was significantly reduced in steroid-treated skin compared to control skin. Our results indicate that topical glucocorticoid treatment can suppress histamine release from dermal mast cells in man. SN - 0001-5555 UR - https://www.unboundmedicine.com/medline/citation/6204486/Effects_of_topically_applied_clobetasol_17_propionate_on_histamine_release_in_human_skin_ L2 - https://antibodies.cancer.gov/detail/CPTC-ITCH-1 DB - PRIME DP - Unbound Medicine ER -